Gen-Probe gets rights to Qualigen's platform:
This article was originally published in Clinica
Executive Summary
In what may accelerate its entry into the clinical point-of-care (POC) testing market, nucleic acid test (NAT) maker Gen-Probe has gained exclusive rights to the immunoassay technology behind Qualigen's blood testing system, FastPack. Gen-Probe hopes access to the technology will help it develop a POC NAT system that can identify harmful micro-organisms and genetic mutations, for use in doctors' offices, outpatient clinics and blood screening centres. The San Diego, California firm will pay Qualigen an initial $1m for an 18-month option to license on an exclusive basis.